+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Generic Oncology Drugs Market to 2027 - Global Analysis and Forecasts by Molecular Type; Indication, and Geography

  • ID: 4841373
  • Report
  • Region: Global
  • 152 pages
  • The Insight Partners
UP TO OFF
until Jan 15th 2020
1 of 3

FEATURED COMPANIES

  • Aurobindo Pharma
  • Cipla Inc.
  • Fresenius Kabi AG
  • Glenmark
  • Intas Pharmaceuticals
  • MSN Laboratories
  • MORE
The global generic oncology drugs market is expected to reach US$ 36,029.60 Mn in 2027 from US$ 21,200.00 in 2018. The market is estimated to grow with a CAGR of 6.3% from 2019-2027.

Factors such as, growing cancer prevalence across the globe, new product launches and benefits offered by generic drugs are boosting the market over the years. In addition, the growing pharmaceutical industry in developing countries are likely to have a positive impact on the growth of the market in the coming years.

Generic drugs are copies of branded drugs. Their pharmacological effects are similar to the branded counterparts. Generic drugs are cost effective as the manufacturers have not invested in the development and marketing of the new drug. When a drug patent expires, other manufacturers apply for FDA approval in order to manufacture and sell the product. Hence generic drugs are cheaper than branded drugs. The generic drug have exactly the same effects, dosage, side effects, route of administration, safety, risks, and strength as the original branded drug. Generic drugs are important in oncology as some anticancer drugs are only offered as generics. In most of the cases like, children with acute lymphoblastic leukemia or women patients with early-stage breast cancer are treated with generics. Generic drugs are extensively used in supportive care. The most significant benefit of using generic drugs is the cost, which is up to 85% less than that of a branded drugs. Thus, these benefits offered by generic drugs is likely to enhance the market growth during the forecast period.

The global generic oncology drugs market, based on the indication was segmented into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, kidney cancer, cervical cancer, others. In 2018, the lung cancer segment held the largest share of the market, by indication. The highest share of lung cancer segment attributes to the high prevalence of patients suffering with the lung cancer that can be treated with generic oncology drugs.

Some of the major primary and secondary sources included in the report for the Generic Oncology Drugs Market are the World Health Organization, British Generics Manufacturers Association, Centers for Disease Control and Prevention, Cancer Association of South Africa, Italian Association for Cancer Research, American Cancer Society, Indian Brand Equity Foundation, and others.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aurobindo Pharma
  • Cipla Inc.
  • Fresenius Kabi AG
  • Glenmark
  • Intas Pharmaceuticals
  • MSN Laboratories
  • MORE
1. Introduction
1.1 Scope of the Study
1.2 Report Guidance
1.3 Market Segmentation
1.3.1 Global Generic Oncology Drugs Market - By Molecule Type
1.3.2 Global Generic Oncology Drugs Market - By Application
1.3.3 Global Generic Oncology Drugs Market - By Geography

2. Global Generic Oncology Drugs Market - Key Takeaways

3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Global Generic Oncology Drugs- Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific - PEST Analysis
4.2.4 Middle East & Africa- PEST Analysis
4.2.5 South & Central America - PEST Analysis
4.3 Expert Opinions

5. Global Generic Oncology Drugs Market - Key Industry Dynamics
5.1 Key Market Drivers
5.1.1 Growing Cancer Prevalence Across The Globe
5.1.2 New Drug Launches
5.1.3 Benefits Offered By Generic Drugs
5.2 Key Market Restraints
5.2.1 Pricing Pressure
5.3 Key Market Opportunities
5.3.1 Growing Pharmaceutical Industry in Emerging Economies
5.4 Future Trends
5.4.1 Inclination Towards Personalized Medicine
5.5 Impact Analysis

6. Generic Oncology Drugs Market - Global Analysis
6.1 Global Generic Oncology Drugs Market Revenue Forecasts And Analysis
6.2 Global Generic Oncology Drugs Market, By Geography - Forecasts And Analysis
6.3 Market Positioning of Key Players

7. Generic Oncology Drugs Market Analysis And Forecasts To 2027 - Molecule Type
7.1 Overview
7.2 Global Generic Oncology Drugs Market Share by Molecule Type 2018 & 2027 (%)
7.3 Large Molecules Market
7.3.1 Overview
7.3.2 Large Molecules Market Revenue and Forecast to 2027 (US$ Mn)
7.4 Small Molecules Market
7.4.1 Overview
7.4.2 Small Molecules Market Revenue and Forecast to 2027 (US$ Mn)

8. Generic Oncology Drugs Market Analysis And Forecasts To 2027 - Indication
8.1 Overview
8.2 Global Generic Oncology Drugs Market Share by Indication 2018 & 2027 (%)
8.3 Lung Cancer
8.3.1 Overview
8.3.2 Lung Cancer Market Revenue and Forecast to 2027 (US$ Mn)
8.4 Stomach Cancer
8.4.1 Overview
8.4.2 Stomach Cancer Market Revenue and Forecast to 2027 (US$ Mn)
8.5 Colorectal Cancer
8.5.1 Overview
8.5.2 Colorectal Cancer Market Revenue and Forecast to 2027 (US$ Mn)
8.6 Breast Cancer
8.6.1 Overview
8.6.2 Breast Cancer Market Revenue and Forecast to 2027 (US$ Mn)
8.7 Prostate Cancer
8.7.1 Overview
8.7.2 Prostate Cancer Market Revenue and Forecast to 2027 (US$ Mn)
8.8 Liver Cancer
8.8.1 Overview
8.8.2 Liver Cancer Market Revenue and Forecast to 2027 (US$ Mn)
8.9 Kidney Cancer
8.9.1 Overview
8.9.2 Kidney Cancer Market Revenue and Forecast to 2027 (US$ Mn)
8.10 Cervical Cancer
8.10.1 Overview
8.10.2 Cervical Cancer Market Revenue and Forecast to 2027 (US$ Mn)
8.11 Others
8.11.1 Overview
8.11.2 Others Market Revenue and Forecast to 2027 (US$ Mn)

9. Generic Oncology Drugs Market Revenue and Forecasts to 2027 - Geographical Analysis
9.1 North America Generic Oncology Drugs Market Revenue And Forecasts To 2027
9.1.1 North America Generic Oncology Drugs market Revenue and Forecasts to 2027 (US$ Mn)
9.2 North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
9.3 North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
9.3.1 North America Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
9.3.2 US Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.3.2.1 US Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.3.2.2 US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
9.3.2.3 US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
9.3.3 Canada Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.3.3.1 Canada Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.3.4 Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
9.3.5 Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
9.3.6 Mexico Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.3.6.1 Mexico Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.3.7 Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
9.3.8 Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
9.4 Europe Generic Oncology Drugs Market Revenue And Forecasts To 2027
9.4.1 Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.5 Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
9.6 Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
9.6.1 Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
9.6.2 UK Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.6.2.1 UK Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.6.3 UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
9.6.4 UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
9.6.5 Germany Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.6.5.1 Germany Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.6.6 Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
9.6.7 Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
9.6.8 France Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.6.8.1 France Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.6.9 France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
9.6.10 France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
9.6.11 Italy Generic oncology drugs market Revenue and Forecasts to 2027 (US$ Mn)
9.6.11.1 Italy Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.6.12 Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
9.6.13 Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
9.6.14 Spain Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.6.14.1 Spain Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
9.6.15 Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
9.6.16 Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10. Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027
10.1 Overview
10.2 Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
10.3 Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
10.4 Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
10.5 Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
10.6 Japan Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
10.6.1 Japan Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
10.6.2 Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
10.6.3 Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
10.7 China Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
10.7.1 China Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
10.7.2 South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
10.7.3 China Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
10.8 India Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
10.8.1 India Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
10.8.2 India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
10.8.3 India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
10.9 Australia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
10.9.1 Australia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
10.9.2 Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
10.9.3 Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
10.10 South Korea Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
10.10.1 South Korea Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
10.10.2 South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
10.10.3 South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

11. Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027
11.1 Overview
11.2 Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
11.3 Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
11.4 Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
11.5 Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
11.6 South Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
11.6.1 South Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
11.6.2 South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
11.6.3 South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
11.7 Saudi Arabia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
11.7.1 Saudi Arabia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
11.7.2 Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
11.7.3 Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
11.8 UAE Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
11.8.1 UAE Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
11.8.2 UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
11.8.3 UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

12. South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027
12.1 Overview
12.2 South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
12.3 South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
12.4 South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
12.5 South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)
12.6 Brazil Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
12.6.1.1 Brazil Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
12.6.2 Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
12.6.3 Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)
12.6.4 Argentina Generic Oncology Drugs Market
12.6.4.1 Argentina Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)
12.6.5 Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)
12.6.6 Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

13. Generic Oncology Drugs Market - Industry Landscape
13.1 Overview
13.2 Growth Strategies in the Generic Oncology Drugs Market, 2016-2019
13.3 Organic Growth Strategies
13.4 Inorganic Growth Strategies

14. Generic Oncology Drugs Market-Key Company Profiles
14.1 Dr. Reddy's Laboratories Ltd
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Financial Overview
14.1.4 Product Portfolio
14.1.5 SWOT Analysis
14.1.6 Key Developments
14.2 Fresenius Kabi AG
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Financial Overview
14.2.4 Product Portfolio
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Cipla Inc.
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Financial Overview
14.3.4 Product Portfolio
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 Mylan N.V.
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Financial Overview
14.4.4 Product Portfolio
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Zydus Cadila
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Financial Overview
14.5.4 Product portfolio
14.5.5 SWOT Analysis
14.5.6 KEY DEVELOPMENTS
14.6 Intas Pharmaceuticals
14.6.1 Key Facts
14.6.2 Business Description
14.6.3 Financial Information
14.6.4 Product Portfolio
14.6.5 SWOT Analysis
14.6.6 Key Developments
14.7 Aurobindo Pharma
14.7.1 Key Facts
14.7.2 Business Description
14.7.3 Financial Overview
14.7.4 Product Portfolio
14.7.5 SWOT Analysis
14.7.6 Key Developments
14.8 Teva Pharmaceutical Industries Ltd.
14.8.1 Key Facts
14.8.2 Business Description
14.8.3 Financial Overview
14.8.4 Product Portfolio
14.8.5 SWOT Analysis
14.8.6 Key Developments
14.9 Sandoz International GmbH (A Division of Novartis AG)
14.9.1 Key Facts
14.9.2 Business Description
14.9.3 Financial Overview
14.9.4 Product Portfolio
14.9.5 SWOT Analysis
14.9.6 Key Developments
14.10 Glenmark
14.10.1 Key Facts
14.10.2 Business Description
14.10.3 Financial Overview
14.10.4 Product Portfolio
14.10.5 SWOT Analysis
14.10.6 Key Developments
14.11 Sun Pharmaceutical Industries Ltd.
14.11.1 Key Facts
14.11.2 Business Description
14.11.3 Financial Overview
14.11.4 Product Portfolio
14.11.5 SWOT Analysis
14.11.6 Key Developments
14.12 MSN Laboratories
14.12.1 Key Facts
14.12.2 Business Description
14.12.3 Financial Overview
14.12.4 Product Portfolio
14.12.5 SWOT Analysis
14.12.6 Key Developments

15. Appendix
15.1 About the Publishers
15.2 Glossary Of Terms
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GMBH
  • Glenmark
  • Sun Pharmaceutical Industries Ltd
  • MSN Laboratories
  • Aurobindo Pharma
  • Intas Pharmaceuticals
  • Zydus Cadila
  • Mylan N.V.
  • Cipla Inc.
  • Fresenius Kabi AG
  • Dr. Reddy’s Laboratories Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll